The rationale for the combined use of genetically engineered biological drugs in patients with COVID-19


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Currently, there are no clinical trial data to recommend the use of combinations of genetically engineered biological drugs in the treatment of patients with COVID-19. Clinical data on the sequential use of various genetically engineered biological drugs are contradictory. The combined use of genetically engineered biological drugs may increase the risk of suppression of the immune system. The use of Janus kinase inhibitors in combination with biological disease-modifying antirheumatic drug is not recommended.

Texto integral

Acesso é fechado

Sobre autores

I. Burashnikova

Kazan State Medical Academy - Branch Campus of the Russian Medical Academy of Continuous Professional Education

Kazan, Russia

Bibliografia

  1. Mehta P., McAuley D.F, Brown M., et al. Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-34. doi: 10.1016/S0140-6736(20)30628-0.
  2. Huang C, Wang Y, Li X, et a!. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506 doi: 10.1016/S0140-6736(20)30183-5.
  3. Choudhary S., Sharma K., Silakari O. The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options. Microb Pathog. 2021;150:104673. doi: 10.1016/j.micpath.2020.104673.
  4. Wolf J., Rose-John S., Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine. 2014;70:11-20. Doi: 10.1016/j. cyto.2014.05.024.
  5. Karki R., Sharma B.R., Tuladhar S., et al. Synergism of TNF-а and IFN-y Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes. Cell. 2021;184(1):149-68.e17. Doi: 10.1016/j. cell.2020.11.025.
  6. Wu D., Yang X.O. Th17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor fedratinib. J Microbiol Immunol Infect. 202053(3):368-70. Doi: 10.1016/j. jmii.2020.03.005.
  7. Pacha O., Sallman M.A., Evans S.E. COVID-19: a case for inhibiting IL-17? Nat Rev Immunol. 2020;20(6):345-46. doi: 10.1038/s41577-020-0328-z.
  8. Liu Y., Yang Y, Zhang C., et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020;63(3):364-74. Doi: 10.1007/ s11427-020-1643-8.
  9. Kritas S.K, Ronconi G., Caraffa A., et al. Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy. J Biol Regul Homeost Agents. 2020;34(1):9-14. doi: 10.23812/20-Editorial-Kritas.
  10. Conti P., Caraffa A., Gallenga C.E., et al. IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra). J Biol Regul Homeost Agents. 2020;34(5):1623-27. doi: 10.23812/20-34-4EDIT-65.
  11. Man S.M., Karki R., Kanneganti T.D. Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases. Immunol Rev. 2017;277:61-75. doi: 10.1111/imr.12534.
  12. Anakinra (Kineret) Prescribing Information. Food and Drug Administration. 2012. Available at: https://www.accessdata.fda.gov/drugsatfda_ docs/label/2012/103950s5136lbl.pdf. (Accessed April 8, 2020).
  13. Richardson P., Griffin I., Tucker C., et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30-1. doi: 10.1016/S0140-6736(20) 30304-4.
  14. Bronte V., Ugel S., Tinazzi E. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Invest. 2020;130:6409-406. doi: 10.1172/JCI141772.
  15. Maslennikov R., Ivashkin V., Vasilieva E., et al. Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19 [published online ahead of print, 2021 May 21]. Pulm Pharmacol Ther 2021;69:102039. Doi: 10.1016/j. pupt.2021.102039.
  16. Khani E., Khiali S., Entezari-Maleki T. Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review. J Clin Pharmacol. 2021;61(4):429-60. Doi: 10.1002fjcph.1822.
  17. Siemieniuk R.A., Bartoszko J.J., Ge L., et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020;370:m2980. doi: 10.1136/bmj.m2980.
  18. Kim J.S.,lee J.Y,Yang J.W.,et al.Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics. 2021;11(1):316-29. Doi: 10.7150/ thno.49713.
  19. Seif F., Pornour M., Mansouri D. Combination of JAKinibs with Methotrexate or Anti-Cytokine Biologics in Patients with Severe COVID-19. Int Arch Allergy Immunol. 2020;181(8):648-49. doi: 10.1159/000509198.
  20. Gremese E., Alivernini S., Tolusso B., et al. JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy. J Leukoc. Biol. 2019;106(5):1063-68. Doi: 10.1002/ JLB.5RU0519-145R.
  21. Методические рекомендации «Особенности клинических проявлений и лечения заболевания, вызванного новой коронавирусной инфекцией (COVID-19) у детей». Версия 2.
  22. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 11 (07.05.2021)
  23. URL: https://www.covid19treatmentguidelines.nih.gov/immunomodulators/Accessed 06.06.2021
  24. URL: https://app.magicapp.org/ff/guideline/L4Q5An/rec/Lq4Y0j Accessed 06.06.2021
  25. URL: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/clinical-management-covid-19.html#a83
  26. Rebonato M.A., D'Adamo F., Capalbo M., Frausini G. Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis. Respir. Med. Case Rep. 2020;31:101115. doi: 10.1016/j.rmcr.2020.101115.
  27. Aomar-Millan, Francisco I., et al. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study. Intern Emerg Med. 2021;1-10. doi: 10.1007/s11739-020-02600-z.
  28. Maes B., Bosteels C., De Leeuw E., et al. Bart Lambrecht Trials. 2020;21:468. (Published on-line 2020 Jun 3). doi: 10.1186/s13063-020-04453-
  29. URL: https://clinicaltrials.gov/ct2/show/study/ NCT04330638.
  30. URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001963-10/FR
  31. URL: https://clinicaltrials.gov/ct2/show/NCT0433 5305?term=NCT04335305&draw=2&rank=1
  32. Rubsamen R., Burkholz S., Massey C., et al. Anti-IL-6 Versus Anti-IL-6R Blocking Antibodies to Treat Acute Ebola Infection in BALB/c Mice: Potential Implications for Treating Cytokine Release Syndrome. Front Pharmacol. 2020;11:574703. Doi: 10.3389/ fphar.2020.574703.
  33. Клинический протокол лечения больных новой коронавирусной инфекцией COVID-19, находящихся на стационарном лечении в медицинских организациях государственной системы здравоохранения города Москвы. 2020
  34. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=aeba7a96-640f-4474-8a57-e343a7d864d3&t
  35. URL: https://www.roche.ru/content/dam/rochexx/roche-ru/roche_russia/ru_RU/Instructions/ actemra-iv-2021-02-09.pdf
  36. Stallmach A., Kortgen A., Gonnert F., et al. Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure - a cautionary case series. Crit Care. 2020;24(1):444. Doi: 10.1186/ s13054-020-03158-0
  37. URL: https://clinicaltrials.gov/ct2/show/NCT04425538?term=infliximab&cond=Covid19&draw=2& rank=1
  38. Kennedy N.A., et al. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut. 2021;70(5):865-875. (Published Online First: 22 March 2021). doi: 10.1136/gutjnl-2021-324388.
  39. URL: https://clinicaltrials.gov/ct2/show/NCT0473 4678?term=infliximab&cond=Covid19&draw=2& rank=2
  40. Cingolani A., Tummolo A.M., Montemurro G., et al. Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab. Infection. 2020;48(5):767-71. Doi: 10.1007/ s15010-020-01476-7.
  41. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=8f3091a1-76a1-4bbd-a3db-b96e103ac7b7&t=
  42. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=fc646e04-eab0-48a2-8a89-978afa294491&t=

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2021

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies